Literature DB >> 22551368

Primary pleomorphic liposarcoma of the orbit: a case report.

Madeline Doyle1, Alexandre N Odashiro, Patrícia R Pereira, Macanori Odashiro, Fernando Kobayashi, Ilton Shinzato, Miguel N Burnier.   

Abstract

To our knowledge, pleomorphic liposarcoma (PL) of the orbit has only been reported in the literature four times. This rarity makes it more difficult to diagnose and to treat in this clinical setting. A 62-year-old female presented with pruritus, edema, proptosis and diplopia 5 months OS. Imaging revealed an intraorbital mass displacing the globe, with infiltration into the sinus. The tumor was removed and the histological examination revealed a highly cellular tumor with heterogenous histology, with a few vacuolated cells and many malignant features. Immunohistochemistry allowed for the differential diagnosis, resulting in a diagnosis of PL of the orbit. The cells were immuno-positive for S-100 and negative for all other relevant markers. According to the literature, prognosis for this neoplasm is quite poor, and exenteration represents the best treatment option. The patient refused exenteration and radiation therapy, however, at 2 year follow-up, she remained recurrence-free.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22551368     DOI: 10.3109/01676830.2011.648806

Source DB:  PubMed          Journal:  Orbit        ISSN: 0167-6830


  3 in total

1.  Primary Pleomorphic Liposarcoma of Fallopian Tube with Recurrence: A Case Report and Review of the Literature.

Authors:  Lianwei Wang; Runlan Luo; Jinming Xu; Dengyang Fang
Journal:  Open Med (Wars)       Date:  2017-12-29

2.  Carunclar Mass as the Presenting Sign of Primary Orbital Liposarcoma.

Authors:  Reza Nabie; Monireh Halimi; Erfan Bahramani; Banafsheh Kharrazi Ghadim
Journal:  Middle East Afr J Ophthalmol       Date:  2019-09-30

3.  Primary orbital pleomorphic liposarcoma in a child: A case report.

Authors:  Trakanta Wannapanich; Paitoon Pratipanawat
Journal:  Am J Ophthalmol Case Rep       Date:  2022-01-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.